Emergency
Staff have revealed they're being forced to release people who are still seriously unwell, simply because there aren't enough beds.
CCTV and internal figures show patients in crisis and waiting almost four days for care in one of the country's busiest emergency departments. The delays are fuelling violence and unsafe discharges.
The situation has prompted scores of psychiatrists to leave the public system in NSW, many accusing the government of not taking mental health seriously or providing the funding the system needs to survive.
This week, Four Corners goes inside the system to investigate the extent of the crisis and the impact on those who need its care the most.
Emergency, reported by Avani Dias and produced by Amy Donaldson, goes to air on Monday 2 June at 8.30pm on ABC TV and ABC iview.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
40 minutes ago
- News.com.au
Why former Ramsay boss sees EMVision's portable stroke detection tech as game-changing
Former Ramsay boss and new EMVision director Carmel Monaghan believes its early stroke detection tech can transform lives Monaghan says EMVision is filling a gap in the market which could improve stroke outcomes Leading stroke centres in Australia and US taking part in pivotal trial for EMVision's first device, the emu bedside scanner EMVision's newest high-profile board director Carmel Monaghan believes the company's technology for early detection of stroke has the potential to "transform people's lives". Monaghan, who has joined the EMVision board as a non-executive director, stepped down this month from Ramsay Health Care (ASX:RHC) after five years as CEO of Ramsay Australia. Ramsay is Australia's largest private hospital operator and offers a range of multidisciplinary healthcare services along with extensive operations internationally. "EMVision is filling a gap in the market, and I've been impressed with the level of research undertaken over the last seven or eight years to bring rapid portable stroke sensing and imaging to point of care, which will really transform people's lives," Monaghan told Stockhead. "We know that time is brain in stroke diagnostics so getting quick, easy access to that neurodiagnostic solution can lead to a much-improved outcome." EMVision is currently undertaking a pivotal trial to support US Food and Drug (FDA) de novo (new device) clearance for its first commercial device – the emu bedside scanner – which is designed to rapidly diagnose stroke at the point-of-care. If granted clearance emu is anticipated to become the predicate device for its second device, First Responder, allowing an expedited 510(k) FDA pathway for the pre-hospital market. Leading stroke centres in Australia and the US are taking part in the trial including Mount Sinai Hospital in New York, Houston's Memorial Hermann-Texas Medical Center and the Mayo Clinic in Florida. EMV is also advancing a strategy to drive ongoing device innovation, refine its algorithms and generate data to support potential expansion of indications to include traumatic brain injury (TBI). This work forms part of EMVision's Continuous Innovation Study, which has received ethics approval to start scanning patients with suspected stroke or TBI at Brisbane's Princess Alexandra Hospital and Newcastle's John Hunter Hospital – both high-volume, comprehensive stroke and level-one trauma centres. Interest in advancing medical innovation Monaghan brings nearly 30 years of experience across hospital, corporate, and international roles at Ramsay. Before becoming CEO in 2020, she served as group chief of staff for Ramsay's global operations, gaining deep operational and strategic insight into the healthcare sector in both Australia and overseas. Monaghan also held the role of group head of marketing and public affairs, where she led the company's marketing, brand and communications strategy during a period of significant global expansion that saw Ramsay become one of the world's leading private healthcare operators. "I'm passionate about enhancing patient care through emphasising and embedding research and clinical trials into operations," Monaghan said. "I drove the expansion of clinical trials at Ramsay because I could see how this made a difference to clinical outcomes and people's lives. "At any one time, we had more than 250 clinical trials being undertaken at Ramsay facilities. "I am really interested in getting research to implementation and giving people hope and that has been a big passion of mine and what I love about medicine." Monaghan emphasised that whether it's drugs or devices, the goal is the same – to test and prove their impact, ultimately improving not just mortality rates but quality of life for people living with the burden of disease. "I've seen it with cancer drugs, robotic technology and that is what attracted me to EMVision. "It is health innovation with purpose and impact." World-renowned clinical team Monaghan noted EMVision's impressive technical, clinical and leadership team. She joins vastly experienced clinicians, medtech and business leaders on the board. The company's clinical advisory group also includes world-leading clinicians, working to address a strong clinical need. "EMVision have world-leading neurologists advising them along with huge luminary hospitals in the US like Mayo and Mt Sinnai, which are now scanning and enrolling patients,' she said, noting there are around 12.5 million strokes globally each year with 6.5 million dying annually. "It is a big burden of disease and one in four people globally over 25 will have a stroke in their lifetime, which has increased 50% over the past 17 years. "With stroke every minute counts and the outcome is heavily influenced by how quick the treatment is delivered. "Both the emu and First Responder will fill a gap where CT is just not practical and means the clinician who needs to make a quick treatment decision can do that effectively." She added that in the future there will also be interest in how the devices could be used to promptly diagnose TBI. "That is down the track, but it has great potential with studies underway at the John Hunter and the Princess Alexandra Hospital that will allow us to begin evaluating traumatic brain injury using our technology." Australia's global edge in health innovation Mongahan said Australia had long punched above its weight in health innovation, producing homegrown companies that have made a global impact. From hospitals to high-tech medical devices, the nation has cultivated a strong foundation in scientific research and clinical excellence – factors that continue to drive international success. She pointed to ASX-listed healthcare heavyweights such as Ramsay, blood products leader CSL (ASX:CSL), hearing implant pioneer Cochlear (ASX:COH), diagnostics and imaging specialist Sonic Healthcare (ASX:SHL), and sleep disorder device manufacturer ResMed (ASX:RMD) as world-class companies. "I have always admired how fantastic Australia is with healthcare and it's because we have such well-trained doctors and good scientific research," she said. "They've all been amazing, admirable companies which have been able to successfully transition overseas. "I think it's exciting how Australia has always performed so strongly in the health field, driven by world-class scientific research and highly trained medical professionals." At Stockhead, we tell it like it is. While EMVision is a Stockhead advertiser, it did not sponsor this article.
News.com.au
an hour ago
- News.com.au
Labor lifts US beef ban amid tariff talks
Australia is lifting a ban on US beef from cattle originating in third countries, a senior minister has confirmed. American beef imports have emerged as a key negotiating item in the Albanese government's efforts to secure a tariff carve out. The Trump administration has been pushing for Australia to loosen import rules to include beef from cattle originating in Canada and Mexico but slaughtered in the US. The Prime Minister confirmed last month biosecurity officials were reviewing the request but vowed his government would not 'compromise' Australia's strict bio laws amid outrage from the Nationals and cattle farmers. Confirming reporting overnight that the ban had been lifted, Employment and Workplace Relations Minister Amanda Rishworth denied the Albanese government had not been transparent in its handling of the US demand. 'Obviously, for national security reasons, at times, governments of all persuasions haven't put everything into the public domain,' she told Nine's Today. 'But when it comes to what's known as the beef review … that review has been underway for a decade or over a decade, looking at how we can make sure that our biosecurity is safe. 'We will not compromise on biosecurity. 'That review has been undertaken and the Department of Agriculture, Fisheries and Forestry believe that there are the right controls in place in the US to lift that ban.'
News.com.au
an hour ago
- News.com.au
Prime Minister lifts US beef ban, sets stage for Trump tariff talks
The Prime Minister has moved to dump the ban on US beef imports to Australia that Donald Trump's billionaire trade adviser Howard Lutnick slammed as 'nonsense' in a major olive branch to end the tariff war. The big move removes the Trump administration's key excuse for imposing steep tariffs on Australian beef exports to the US. Australia's bans on fresh beef from the US was to protect against foot-and-mouth outbreak that could cost Australia $80 billion and Mad Cow disease. But in late 2024 and early 2025, the US introduced more robust movement controls which means that all cattle, from Canada and Mexico, can be identified and traced to the farm and through the supply chain. The Albanese Government confirmed the big move on Thursday with government sources confirming it was communicated to the US government overnight Wednesday (AEST). 'The Albanese Labor Government will never compromise on biosecurity,'' Agriculture, Fisheries and Forestry Minister Julie Collins MP: 'The US Beef Imports Review has undergone a rigorous science and risk-based assessment over the past decade. 'The Department of Agriculture, Fisheries and Forestry is satisfied the strengthened control measures put in place by the US effectively manage biosecurity risks. 'Australia stands for open and fair trade – our cattle industry has significantly benefited from this.' The announcement will allow for expanded access to include beef sourced from cattle born in Canada or Mexico which is legally imported and slaughtered in the US. Despite the recent tariff war, Australian beef has had back-to-back record-breaking export years, with last year worth $14 billion. The Albanese maintains it was a Departmental decision based on scientific advice following a review of the restrictions initiated more than 18 months ago, prior to Donald Trump re-election as President for a second term. The US buys in fresh beef from central and South America, where outbreaks of these diseases have been reported. Prime minister Anthony Albanese had previously warned we won't back down on biosecurity protections. 'The beef issue was about mad cow disease and about also the fact that beef to Australia couldn't be guaranteed – whether it had also come from Canada or Mexico as well,' he said at a media conference. Mr Lutnick, who is the US Commerce Secretary had rubbished Anthony Albanese's claims that the laws are to protect Australia from diseases insisting it is simply a protectionist tactic to block American imports. 'Our farmers are blocked from selling almost anywhere. Europe won't let us sell beef, Australia won't let us sell beef,' Mr Lutnick said. The interviewer interjected to say this was 'because of hormonal chemicals'. Lutnick replied: 'No, no, that's not why. It's because they just wanna protect, they want to say: oh, what, the seeds are different? Other people in the world are using seeds? Come on, this is nonsense. This is all nonsense. What happens is they block our markets.' 'When we open those markets ...the price of groceries will come down. Let Donald Trump run the global economy. He knows what he's doing. Let him fix it. Let Donald Trump fix the US economy.' As Australia fights to secure a better deal Mr Lutnick had also warned the US President 'won't back off.' 'I don't think there's any chance the President is going to back off the tariffs. This is the reordering of global trade,'' Mr Lutnick told CNN on Friday AEDT. 'The president is not going to back off. But countries can fix their tariffs, their non-tariff trade barriers, which are much, much rougher. They are the monster that needs to be slayed. 'Then, and only then, will Donald Trump make a deal with each country – when they've really, really changed their ways.' 'Negotiate is talking. No talking. Too late. These countries have abused us and exploited us, as he said yesterday. They need to change their ways, let's see them change their ways. It's going to be a long time, let's see what they do. Not talking. Talking is nonsense.' Mr Lutnick previously come out swinging against Australia as he strongly defended the 25 per cent tariffs imposed by the Trump administration on steel and aluminium 'Look, you've got dumpers in the rest of the world. Japan dumps steel. China dumps steel. What that means is they make it, they over produce and they sell it dirt cheap to try to drive our guys out of business,' he said. 'The President is here to protect American workers. He's here to protect American industry. We're going to stop that nonsense and bring steel here.
